Agenus

Bristol Myers culls cell therapy deals with 2 biotechs

BMS has terminated cell therapy pacts with two biotechs amid "portfolio prioritization efforts” within the pharma, one of the affected companies said.

Gabrielle Masson Dec 16, 2024 11:19am

BMS ditches TIGIT, ending $200M bet on Agenus bispecific

Aug 5, 2024 9:17am

Image of a neon sign with the word no lit up next to an unlit yes

FDA wrecks Agenus’ accelerated approval plan

Jul 18, 2024 8:01am

BMS trims anti-TIGIT and a handful of other meds

Sep 14, 2023 1:57pm

graphic image of stick figures being pushed out of a line indicating theyre being removed or fired

Agenus lays off 25%, sidelines programs to focus on cancer combo

Aug 23, 2023 11:04am

Agenus gets boost for combo drug, this time in ovarian cancer

Mar 27, 2023 9:45am